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Abstract
Despite the different features of diabetes mellitus (DM) in Asian populations compared with Western populations, the impact of
metabolic syndrome (MetS) on long-term mortality according to DM status has not yet been elucidated in the Asian population.
After performing 1:1 propensity score matching (PSM) using clinical variables including age, gender, smoking, and individual MetS
components between DM and non-DM subjects from the data of the Korea Initiatives on Coronary Artery Calciﬁcation registry,
mortality was evaluated according to DM and MetS in 14,956 asymptomatic Korean subjects.
The mean follow-up duration was 53.1 months (interquartile range: 33–80). The overall prevalence of MetS was 60%. DM subjects
had higher mortality compared with non-DM subjects (1.2% vs 0.7%, respectively; P=0.001); the cumulative mortality by
Kaplan–Meier analysis was higher in DM subjects than in non-DM subjects (log-rank P=0.001). DM increased the risk of mortality in
PSM participants (hazard ratio [HR] 1.74; P=0.001). In non-DM subjects, MetS (HR 2.32) and one of its components, central obesity
(HR 1.97), were associated with an increased risk of mortality (bothP<0.05). In contrast, there was no signiﬁcant difference in the risk
of mortality according to MetS or its components in DM subjects. After adjusting for confounding risk factors, it was shown that MetS
independently increased the risk of mortality in non-DM subjects.
Compared with non-DM subjects, DM subjects have an increased risk of long-term mortality among PSM participants. MetS
appears to have an independent impact on mortality in subjects without established DM among the asymptomatic Korean
population. Our results may not be applicable to the whole subjects with MetS because the PSM using MetS components was
performed between subjects with and without DM which was very high risk for adverse clinical events.
Abbreviations: BP = blood pressure, CACS = coronary artery calcium score, CI = conﬁdence interval, CKD = chronic kidney
disease, DM = diabetes mellitus, FRS = Framingham risk score, GFR = glomerular ﬁltration rate, HbA1c = glycosylated hemoglobin,
HDL = high-density lipoprotein, HR = hazard ratio, LDL = low-density lipoprotein, MetS = metabolic syndrome, PSM = propensity
score matching.
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11. Introduction
Diabetes mellitus (DM) increases the risk of all-cause and
cardiovascular mortality.[1–4] It is well established that an
aggravation of insulin resistance and a deterioration of insulin
secretion are 2 central defects in DM pathogenesis.[5,6] However,
the clinical features of DM in Asia are explicitly different from
those in other parts of the world.[7] Several previous studies in a
Korean population have reported that impaired insulin secretion
is more prominent than insulin resistance, even in the status of
impaired glucose tolerance and type 2 DM.[8,9]
Metabolic syndrome (MetS) is a concurrence of impaired
glucose intolerance, abdominal obesity, dyslipidemia, and
hypertension; insulin resistance is a major characteristic.[10,11]
The prevalence of MetS is rapidly increasing worldwide and
affects approximately 31% of Korean adults.[12,13] MetS has
many characteristics in common with DM, and according to
some classiﬁcations, has been identiﬁed as a risk factor for DM
development. However, the numerous deﬁnitions of MetS have
concurrently included established DM as part of the diagnostic
criteria of MetS. The World Health Organization recently
recommended that established DM should be excluded from
the deﬁnition of MetS.[14] However, there is a paucity of data
Table 1
Clinical characteristics of PSM participants.
Characteristics
Non-DM
(n=7478)
DM
(n=7478) P
Age, y 56±8 56±9 0.180
Male, n (%) 6111 (81.7) 6052 (80.9) 0.216
Current smoking, n (%) 1761 (23.5) 1789 (23.9) 0.692
MetS, n (%) 4480 (59.9) 4458 (59.6) 0.714
MetS components, n (%)
Central obesity 3860 (51.6) 3862 (51.6) 0.974
Increased BP 5414 (72.4) 5499 (73.5) 0.118
Increased triglyceride 2673 (35.7) 2669 (35.7) 0.946
Decreased HDL 1579 (21.1) 1626 (21.7) 0.349
Antihypertensive drugs, n (%) 2513 (39.0) 2957 (43.6) <0.001
Lipid lowering drugs, n (%) 1436 (22.5) 2025 (30.0) <0.001
Use of aspirin, n (%) 916 (15.7) 1341 (22.5) <0.001
Total cholesterol, mg/dL 201±35 191±37 <0.001
LDL, mg/dL 127±32 119±33 <0.001
Fasting glucose, mg/dL 107±6 121±34 <0.001
GFR, mL/min per 1.73 m2 87±22 88±23 0.226
HbA1c, % 5.7±0.4 6.5±1.2 <0001
CACS ≥ 400 316 (4.3) 445 (6.0) <0.001
BP = blood pressure, CACS = coronary artery calcium score, DM = diabetes mellitus, GFR =
glomerular ﬁltration rate, HbA1c = glycosylated hemoglobin, HDL = high-density lipoprotein, LDL =
low-density lipoprotein, MetS = metabolic syndrome, PSM = propensity score matching.
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signiﬁcance of MetS concept for predicting adverse clinical
outcomes in established DM status. This issue may be more
important in the Asian population than in the worldwide
population considering the different features of DM in Asia. In
the present study, we investigated the impact of MetS on long-
term mortality according to DM status within the concept of
MetS using a large Korean multicenter registry.
2. Methods
2.1. Subjects and study design
We analyzed data from the Korea Initiatives on Coronary Artery
Calciﬁcation (KOICA) multicenter registry. This is a retrospec-
tive, single ethnicity multicenter observational registry in a self-
referral setting for subjects who underwent health check-ups at 3
healthcare centers in South Korea. Between December 2002 and
July 2014, a total of 48,903 subjects were enrolled in this registry,
and the median follow-up duration was 53.1 months (inter-
quartile range: 33–80). Self-reported medical questionnaires were
used for obtaining information about medical history. All data
were acquired at the time of visit at each healthcare center. Of the
48,903 subjects from this registry, 6100 subjects were excluded
from this analysis because of the lack of data for identifying the
status of both MetS and DM. With the remaining subjects, we
performed a 1:1 propensity score matching (PSM) between
patients with and without DM using prespeciﬁed clinical
variables, including age, gender, smoking, and individual MetS
components. Finally, a total of 14,956 subjects composed of
7478 diabetics and 7478 nondiabetics were enrolled in the
present study. The primary endpoint of this study was all-cause
mortality. Ascertainment of mortality was determined by the
Ministry of Security and Public Administration’s query. Inves-
tigations were performed until December 20, 2014 in 2 centers
and September 24, 2014 in the other center. The appropriate
institutional review board committees approved the study
protocol for the 3 healthcare centers.
Information on the medical history of hypertension, diabetes,
and smoking status for each subject was systematically collected.
Height, weight, and blood pressure (BP) were measured during
healthcare center visits. All blood samples were obtained after a
minimum 8-h fast and analyzed for triglycerides, high-density
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, and glucose levels. A subject’s kidney function was
assessed based on the estimated glomerular ﬁltration rate (GFR)
calculated using the formula validated in the Cockcroft-Gault
formula.[15] Chronic kidney disease (CKD) was deﬁned as an
estimated GFR<60mL/min per 1.73m2.MetS was deﬁned as the
presence of ≥3 out of a list of 5 parameters: abdominal obesity
based on waist circumference ≥90cm in males or ≥80cm in
females; systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 mmHg, a
referral diagnosis of hypertension, or on antihypertensive
treatment; HDL cholesterol level <40mg/dL in men or <50
mg/dL in women; fasting triglycerides level ≥150mg/dL; and
impaired fasting glucose, deﬁned as a fasting glucose level ≥100
mg/dL, a referral diagnosis of DM, or on DM treatment
according to the National Cholesterol Education Program—
Adult Treatment Panel III deﬁnition.[10] Diabetes was deﬁned as a
fasting glucose level ≥126mg/dL, glycosylated hemoglobin
(HbA1c) ≥6.5%, undergoing an antidiabetic treatment, or a
referral diagnosis of diabetes.[16] In all of the centers, a coronary
artery calcium scan was performed using a >16 slice multi-
detector computed tomography (CT) scanner. Speciﬁc CT2scanner types used in each center included Philips Brilliance
256 iCT, Philips Brilliance 40 channel MDCT, Siemens 16-slice
Sensation, and GE 64-slice Lightspeed. All 3 centers performed
standard prospective or retrospective methods. The coronary
artery calcium score (CACS) was evaluated on the basis of the
scoring system from a previously described method.[17] In the
present study, we used CACS ≥ 400 as the parameter for
estimating severe coronary calciﬁcation in the present study.2.2. Statistical analysis
Clinical and biochemical characteristics are shown according to
the presence of DM and MetS. Continuous variables are
expressed as the mean± standard deviation, and categorical
variables are presented as absolute counts and percentages.
Differences between continuous variables were analyzed by
Student t test, and those between categorical variables were
analyzed by the x2 test or Fisher exact test, as appropriate.
Kaplan–Meier survival analysis was performed for the cumula-
tive incidence of all-cause death. Comparisons between groups
were performed using the log-rank test. Cox hazard regression
analysis was performed to identify the impact of DM, MetS, and
individual MetS component for all-cause mortality. From the
Cox model, hazard ratios (HRs) and 95% conﬁdence intervals
(CI) were calculated. The forced entry method was used to enter
independent variables into the multiple regression models for
identifying the impact of MetS on mortality. SPSS statistical
software version 20.0 (SPSS, Inc, Chicago, IL) was used for
statistical analyses. Values of P < 0.05 were considered
signiﬁcant.3. Results
3.1. Baseline characteristics
Baseline characteristics of the PSM participants are presented in
Table 1. Compared with non-DM subjects, DM subjects had
signiﬁcantly higher levels of fasting glucose and HbA1c. The
Figure 1. Kaplan–Meier survival analysis for the cumulative mortality according
to DM in propensity score matching participants. DM = diabetes mellitus.
Table 2
Univariate Cox regression analysis for identifying the impact of
MetS and its individual component onmortality according to DM in
PSM participants.
Characteristics HR 95% CI P
Non-DM
MetS 2.32 1.20–4.52 0.013
Central obesity 1.97 1.09–3.55 0.024
Increased BP 1.93 0.94–3.95 0.074
Increased triglycerides 1.14 0.65–1.98 0.651
Decreased HDL 1.08 0.57–2.06 0.819
DM
MetS 1.14 0.74–1.73 0.556
Central obesity 0.91 0.60–1.36 0.635
Increased BP 1.07 0.67–1.71 0.771
Increased triglycerides 1.14 0.75–1.73 0.536
Decreased HDL 1.27 0.80–2.02 0.317
BP = blood pressure, CI = conﬁdence interval, DM = diabetes mellitus, HDL = high-density
lipoprotein, HR = hazard ratio, MetS = metabolic syndrome, PSM = propensity score matching.
Won et al. Medicine (2016) 95:49 www.md-journal.comlevels of total cholesterol were signiﬁcantly lower in DM subjects
than in non-DM subjects. The incidence of CACS > 400 was
signiﬁcantly higher in DM subjects than in non-DM subjects
(6.0% vs 4.3%, respectively; P<0.001). Results of comparing
metabolic abnormalities according to DM in the PSM partic-
ipants that were described as continuous variables were presented
in Supplementary Table 1, http://links.lww.com/MD/B435.
Metabolic abnormalities that were described as continuous
variables according to the number of MetS components in non-
DM and DM participants were presented in Supplementary
Table 2, http://links.lww.com/MD/B435.3.2. Clinical outcomes according to DM and MetS
A total of 144 all-cause deaths occurred during the follow-up
period. The incidence of all-cause death was higher in DM
subjects than in non-DM subjects (0.7% vs 1.2%, respectively;
P=0.001). In the Kaplan–Meier analysis, DM subjects had
higher cumulative mortality compared with nondiabetic subjects
(log-rank P=0.001). Additionally, DM increased the risk of
mortality in PMS participants (HR 1.74; 95% CI 1.24–2.44;
P=0.001) (Fig. 1). In non-DM subjects, MetS subjects had
signiﬁcantly higher cumulative mortality compared with non-
MetS subjects (log-rank P=0.011). However, as shown in Fig. 2,
there was no signiﬁcant difference in the cumulative mortality
according to MetS in DM subjects (log-rank P=0.556).Figure 2. Kaplan–Meier survival analysis for the cumulative mortality accordin
MetS = metabolic syndrome.
33.3. Impact of individual MetS component on the mortality
according to DM
The results of univariate Cox hazard regression analyses to
identify the impact of MetS and its individual components on
mortality according to DM status are presented in Table 2. In
non-DM subjects,MetS (HR 2.32; 95%CI 1.20–4.52; P=0.013)
and central obesity (HR 1.97; 95% CI 1.09–3.55; P=0.024)
among its individual component were signiﬁcantly associated
with an increased risk of mortality. In contrast, there was no
signiﬁcant difference in the risk of mortality according to MetS
and its individual components in DM subjects. In the multivariate
Cox hazard regression analyses after adjusting individual MetS
components as continuous variables also showed consistent
results (Supplementary Table 3, http://links.lww.com/MD/
B435).
3.4. Independent impact of MetS on mortality in
non-DM subjects
Multiple Cox hazard regression models were analyzed to
identify the impact of MetS on mortality in non-DM subjects.
After adjusting consecutive variables including age, gender,
CKD, smoking, and CACS > 400, MetS was independently
associated with the increased risk of mortality in non-DM
subjects (Table 3). In addition, the number of MetS components
was independently associated with the increased risk of mortalityg to MetS in (A) non-DM and (B) DM subjects. DM = diabetes mellitus,
Table 3
Cox regression models for the impact of MetS on mortality in non-
DM participants.
Univariate
MetS HR 95% CI P
Model 1
∗
2.09 1.07–4.07 0.031
Model 2† 2.31 1.18–4.50 0.014
Model 3‡ 2.34 1.19–4.59 0.013
Model 4x 2.34 1.19–4.59 0.013
Model 5jj 2.44 1.20–4.94 0.013
CI = conﬁdence interval, CACS = coronary artery calcium score, CKD = chronic kidney disease,
DM = diabetes mellitus, HR = hazard ratio, MetS = metabolic syndrome.
∗
Adjusted for age.
† Adjusted for age and gender.
‡ Adjusted for age, gender, and CKD.
x Adjusted for age, gender, CKD, and smoking.
jj Adjusted for age, gender, CKD, smoking, and CACS > 400.
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com/MD/B435).4. Discussion
To the best of our knowledge, this PSM study provides the ﬁrst
information on the differential association between MetS and
long-term mortality according to DM status in the asymptomatic
Asian population. There were 2 major ﬁndings: DM subjects had
the increased risk of long-termmortality compared with non-DM
subjects after PSM with abnormal metabolic components and
MetS was independently associated with the increased mortality
only in subjects without established DM.
While MetS is a somewhat reversible condition because its
diagnosisdependsonthenumberofclusteringcomponents,DMisa
chronic and progressive illness that is strongly associated with the
increased risk of mortality.[1–4] It is well known that the clinical
features of DM in Asia (when compared with other parts of the
world)areexplicitlydifferent inDMdevelopedatayoungerageand
in amuch shorter time than in subjects withmuch lower bodymass
index.[7] In clinical practice,MetS has been promoted as ameans of
identifying the risk of DM development because of its major
characteristics.[18]However, establishedDMhasbeenconcurrently
included in the diagnostic criteria for MetS as a component of
impaired fasting glucose. Despite the recent recommendation that
established DM be excluded from the deﬁnition of MetS,[14] data
supporting this recommendation are limited.
A previous study from Aerobics Center Longitudinal Study,
which was performed in a Western population, reported that the
presence of DM is associated with the increased risk of
cardiovascular mortality and that MetS status does not have
an effect on this risk in men.[19] In Korea, a recent cross-sectional
cohort study reported that MetS had an incremental impact on
subclinical atherosclerosis in patients without established
DM.[20] However, a paucity of data on the association between
DM, MetS, and clinical outcomes in Asian populations exists. In
the present study, in an asymptomatic Korean population, DM
subjects had higher long-term mortality compared with non-DM
subjects after 1:1 PSM with individual components of MetS.
Thus, all participants had basically the component of impaired
fasting glucose and might be relatively higher-risk patients
compared with general population.
Interestingly, MetS independently increased the risk of
mortality only in subjects without established DM. Central
obesity was associated with the increased risk of mortality in non-4DM subjects. Previous studies have indicated that adverse clinical
events might be directly dependent on hyperglycemia in DM
subjects but might be inﬂuenced by multiple traditional risk
factors in patients without established DM.[21–23] Moreover,
recent evidence has suggested a close relationship between
glucose ﬂuctuations and adverse clinical outcomes in DM
subjects because of increased oxidative stress responses and
inﬂammatory factors.[24–26] These effects might offset the impact
of MetS and/or its individual components on long-term mortality
in subjects with established DM. Additionally, considering that
central obesity is strongly associated with insulin resistance,
newly developed DM might be associated with increased
mortality in non-DM subjects with central obesity during
follow-up periods. Given the controversy over the deﬁnition of
MetS, the present results indicate that diabetes strongly impacts
long-term mortality irrespective of MetS and presents proper
evidence arguing against the inclusion of established DM in the
classiﬁcation of MetS. Further prospective studies should be
conducted to address these issues in clinical practice.
The International Diabetes Federation (IDF) emphasizes that
central obesity is essential for the diagnosis of MetS.[27]
Furthermore, despite the recent argument on the predictive value
ofMetS for mortality over the Framingham risk score (FRS), waist
circumference appears to have a signiﬁcant role as part of the FRS
provided their cut-off points are optimized.[28] In clinical practice,
there is a paucity of data on the predictive value of the levels of
triglyceride and HDL for adverse clinical outcomes at the era
of statinwhich is improved to reducemortality across awide range
of cholesterol levels inhigh-riskpatients. Inour study,patientswith
DM had signiﬁcantly higher mortality compared with patients
with non-DM despite signiﬁcantly lower LDL levels in the PSM
participants of present study. We could identify that only central
obesity was signiﬁcantly associated with the increased risk of
mortality among all MetS components and the number of MetS
components independently impacted on the increased mortality in
non-DM subjects. These results might strongly support the IDF
deﬁnition that central obesity has a pivotal role in the pathogenesis
of MetS and is a prerequisite for the diagnosis of MetS.
Thepresent studyhas some limitations. First, the incidence of all-
cause death, the primary endpoint, was very small despite the large
sample size of this study. Because the KOICA registry data are
based on the generally healthy population who received health
check-ups in healthcare centers; the number of clinical events at
follow-upwas limited. Second, the present study was retrospective
and might have been inﬂuenced by unobserved confounders.
However, we attempted to minimize the bias effects or confound-
ing factors using the 1:1 PSM analysis. Despite the limitations of
this study, it appears to be unique in that we ﬁrst identiﬁed the
different association between MetS and long-term mortality
according to DM in the asymptomatic Korean population.
Furthermore, to our knowledge, the population size in this study
is the largest to date reporting the impact of MetS on mortality
according to DM status in an Asian population. Considering the
explicitly different clinical features ofDMinAsians comparedwith
Western populations, the results of our studymight provide useful
information for applying the concept of MetS for predicting
adverse clinical outcomes in an Asian population.5. Conclusion
In conclusion, DM subjects have an increased risk of long-term
mortality compared with non-DM subjects after PSM with
metabolic abnormalities. MetS appears to have an independent
[13] Lim S, Shin H, Song JH, et al. Increasing prevalence of metabolic
Won et al. Medicine (2016) 95:49 www.md-journal.comimpact on mortality only in subjects without established DM
among the asymptomatic Korean population. Our results may not
be applicable to the whole subjects with MetS because the PSM
usingMetS components was performed between subjects with and
without DM which was very high risk for adverse clinical events.
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